Abstract
We performed a multicenter prospective randomized controlled trial to determine the efficacy and safety of the surfactant preparation, Survanta (Abbott Laboratories, Chicago, USA), for 750–1750 g infants with idiopathic respiratory distress syndrome, (IRDS) receiving assisted ventilation with 40% or more oxygen. One hundred and six eligible infants from the eight participating centers were randomly assigned between March 1986 and June 1987 to receive either surfactant (100 mg phospholipid/kg, 4 ml/kg) or air (4 ml/kg) administered into the trachea within 8 h of brith (median time of treatment 6.2 h, range 3.2–9.1 h). The study was stopped before enrollment was completed at the request of the United States Food and Drug Administration when significant differences were observed in incidence of periventricular-intraventricular hemorrhage (PIH), between the surfactant treated and control infants. Surfactant treated infants had larger average increases in the arterial-alveolar oxygen ratio, (a/A ratio) (P<0.0001), and larger average decreases in FiO2 (P<0.0001) and mean airway pressure, (MAP) (P<0.017) than controls over the 48 h following treatment. The magnitude of the differences between the surfactant and control groups were 0.19 (SE=0.03) for a/A ratio, −0.28 (SE=0.04) for FiO2 and −1.7 cm H2O (SE=0.70) for MAP. The clinical status on days 7 and 28 after treatment was classified using four predefined ordered categories: (1) no respiratory support; (2) supplemental O2 with or without continuous positive airway pressure (CPAP); (3) intermittent mandatory ventilation; and (4) death. There were no statistically significant differences in the status categories on days 7 or 28 between surfactant and control infants. There were no significant differences between the groups with respect to the incidence of patent ductus arteriosus, bronchopulmonary dysplasia, necrotizing entero-colitis, air leaks or death. There was a statistically significant difference between treated and control infants in the frequency and severity of periventricular-intraventricular hemorrhage (PIH) (Cochran-Mantel-Haenszelχ 2adj=6.36,P=0.01). Hemorrhages occurred in 59.6% of surfactant treated infants and 26.9% of controls. Severe hemorrhages (grades 3 or 4) occurred in 38.5% of surfactant treated infants and 15.4% of controls (χ 2adj=4.01,P=0.045). We conclude that the intratracheal administration of Survanta prior to 8 h of age to infants with IRDS receiving assisted ventilation with 40% or more oxygen results in a reduction in the severity of respiratory distress during the 48 h after therapy. Because of the difference in incidence of PIH between surfactant and control infants in this study, we recommend that future clinical trials of surfactant include more frequent prospective serial ultrasound evaluations for diagnosis of hemorrhage.
Article PDF
Similar content being viewed by others
Abbreviations
- a/A ratio:
-
arterial-alveolar pO2 ratio
- ANOVa:
-
analysis of variance
- BPD:
-
bronchopulmonary dysplasia
- CPAP:
-
continuous positive airway pressure
- FiO2 :
-
fraction of inspired oxygen
- IRDS:
-
idiopathic respiratory distress syndrome
- MAP:
-
mean airway pressure
- NEC:
-
necrotizing enterocolitis
- PaO2 :
-
partial pressure of oxygen in arterial blood
- PAO2 :
-
partial pressure of oxygen in the alveolus
- PaCO2 :
-
partial pressure of carbon dioxide in arterial blood
- PDA:
-
patent ductus arteriosus
- PIH:
-
periventricular-intraventricular hemorrhage
References
Collaborative European Multicenter Study Group (Robertson B) (1988) Surfactant replacement therapy in severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82:683–691
Enhorning G (1988) Clinical experiences from surfactant replacement in North America. In: Jobe A, Taeusch W (ed) Surfactant treatment of lung diseases. Report of the 96th Ross Conference on Pediatric Research, Ross Laboratories, Columbus, Ohio, pp 77–82
Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP, Milligan J (1985) Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics 76:145–153
Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Tadaaki A (1980) Artificial surfactant therapy in hyaline membrane disease. Lancet I:55–59
Fujiwara T, Onishi M, Nanby H, Ogawa Y, Niitsu N, Naito T, Akamatsu H, Tada H, Okuyama K, Nishida K, Imura S, Takeuchi Y, Goto A, Shimura K, Kito H, Kuroyanagi M, Ogino T, Fujimura M, Nakamura M, Ogino T, Fujimura M, Nakamura H, Takemine H, Nakada E, Hashimoto T (1987) Surfactant supplementation treatment of neonatal respiratory distress syndrome (RDS): results of a multifacility cooperative comparative control trial. Shonika Rinsho 40:459–469
Gitlin JD, Soll RF, Parad RB, Horbar JD, Feldman HA, Lucey JF, Taeusch HW (1987) A randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatrics 79:31–37
Halliday HL, McClure G, Reid MMc, Lappin TRJ, Meban C, Thomas PS (1984) Controlled trial of artificial surfactant to prevent respiratory distress syndrome. Lancet I:476–478
Hallman M, Merritt TA, Jarvenpaa AL, Boynton B, Mannino F, Gluck L, Moore T, Edwards D (1985) Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr 106:963–969
Horbar JD (1987) A calculator program for determining indices of neonatal respiratory distress syndrome severity. Am J Perinatol 4:20–23
Horbar JD, Soll RF, Sutherland J, Kotagal U, Philip AGS, Kessler DL, Little G, Edwards W, Vidyasagar D, Raju TNK, Jobe AH, Ikegami M, Mullett MD, Myerberg DZ, McAuliffe TL, Lucey JF (1989) A multicenter randomized placebo-controlled trial surfactant therapy for respiratory distress syndrome. N Engl J Med 320:959–965
Ikagami M, Jobe M, Berry D (1986) A protein that inhibits surfactant in RDS. Biol Neonate 50:121–129
Jobe A, Ikegami M, Glatz T (1981) Duration and characterization of treatment of preterm lambs with natural surfactant. J Clin Invest 67:370–375
Kendig JW, Notter RH, Cox C, Aschner JL, Benn S, Bernstein RM, Hendricks-Munoz K, Maniscalco WM, Metlay LA, Phelps DL, Sinkin RA, Wood BP, Shapiro DL (1988) Surfactant replacement therapy at birth: final analysis and comparisons with similar trials. Pediatrics 82:756–762
Konishi M, Fujiwara T, Naito T, Takeuchi Y, Ogawa Y, Inukai K, Fujimura M, Nakamura H, Hashimoto T (1988) Surfactant replacement therapy in neonatal RDS. Eur J Pediatr 147:20–25
Kwong M, Egan EA, Notter RH, Shapiro DL (1985) Double blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics 76:585–592
Lachman B, Berggren P, Curstedt T, Grossmann G, Robertson B (1982) Combined effects of surfactant substitution and prolongation of inspiration phase in artificially ventilated premature newborn rabbits. Pediatr Res 16:921–927
Lang MJ, Rhodes PG, Reddy S, Kurth CG, Merritt TA, Hall RT (1988) Limitation of the effective use of human surfactant (HS) in established RDS. Pediatr Res 23:513A
Markestad T, Fitzhardinge PM (1981) Growth and development in children recovering from bronchopulmonary dysplasia. J Pediatr 98:597–602
McCord FB, Curstedt T, Halliday HL, McClure G, Reid MMcC, Robertson B (1988) Surfactant treatment and incidence of intraventricular hemorrhage in severe respiratory distress syndrome. Arch Dis Child 63:10–16
Merritt TA, Hallman M, Bloom BT, Berry C, Benirschke K, Sahn D, Key T, Edwards D, Jarvenpaa AL, Pohjavuori M, Kankaanpaa K, Kunnas M, Paatero H, Rapola J, Jaaskelainen J (1986) Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 315:785–790
O'Brien PC, Flemming TR (1979) A multiple testing procedure for clinical trials. Biometrics 35:549–556
Papile L, Burstein J, Burstein R, Koffler H (1978) Incidence and Evolution of subependymal and intraventricular hemorrhage: a study of infants with birthweight less than 1500 grams. J Pediatr 92:529–534
Raju TNK, Bhat R, McCulloch KM, Maeta H, Vidyasagar D, Sobel D, Anderson M, Levy PS, Furner S (1987) Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease. Lancet I:651–656
SAS Users Guides Basics and Statistics Version 5 Edition (1985) SAS Institute Inc, Cary NC.
Soll RF, Duc G, Minoli I, Versmold H, Riegel K, Schachinger H (1988) European study of single dose Surfactant-TA (STA) for treatment of respiratory distress syndrome (RDS). Pediatr Res 23:525A
Soll RF, Hoekstra R, Fangman J, Corbet A, Adams J, James LS, Schulze K, Oh W, Roberts JD (1988) Multicenter trial of single dose surfactant-TA (STA) for prevention of respiratory distress syndrome (RDS) Pediatr Res 23:425A
Taeusch HW, Keough KMW, Williams M, Slavin R, Steele E, Lee AS, Phelps LD, Kariel N, Floros J, Avery ME (1986) Characterization of a bovine surfactant for infants with respiratory distress syndrome. Pediatrics 77:572–581
Taeusch W, Alleyne C, Takahashi A, Fan B, Nguyen T, Franco G (1988) Surfactant for the treatment of respiratory distress syndrome: selected clinical issues. In: Shapiro D (ed) Surfactant replacement therapy. Semin Perinat XII:245–254
Ten Centre Study Group (1987) Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Br Med J 294:991–996
Versmold HT, Kitterman JA, Phibbs RH, Gregory GA, Tooley WH (1981) Aortic blood pressure during the first 12 hours of life in infants with birthweight 610 to 4220 grams. Pediatrics 67:607–613
Wilkinson A, Jenkins PA, Jeffrey JA (1985) Two controlled trials of dry artificial surfactant: early effects and later outcome in babies with surfactant deficiency. Lancet I:287–291
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Horbar, J.D., Soll, R.F., Schachinger, H. et al. A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome. Eur J Pediatr 149, 416–423 (1990). https://doi.org/10.1007/BF02009663
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02009663